CN1048877C - Medicine with intelligence increasing and brain tonic function - Google Patents
Medicine with intelligence increasing and brain tonic function Download PDFInfo
- Publication number
- CN1048877C CN1048877C CN93110081A CN93110081A CN1048877C CN 1048877 C CN1048877 C CN 1048877C CN 93110081 A CN93110081 A CN 93110081A CN 93110081 A CN93110081 A CN 93110081A CN 1048877 C CN1048877 C CN 1048877C
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- intelligence
- brain
- brain tonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 210000004556 brain Anatomy 0.000 title claims abstract description 60
- 230000001256 tonic effect Effects 0.000 title claims description 45
- 229940079593 drug Drugs 0.000 title description 14
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 13
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims description 22
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 6
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 231100000027 toxicology Toxicity 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 208000037848 Metastatic bone disease Diseases 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000003243 Thuja occidentalis Species 0.000 abstract 1
- 235000008109 Thuja occidentalis Nutrition 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 229940048730 senega Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 description 46
- 235000015961 tonic Nutrition 0.000 description 41
- 239000007788 liquid Substances 0.000 description 40
- 238000000034 method Methods 0.000 description 30
- 230000015654 memory Effects 0.000 description 20
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- 230000001575 pathological effect Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 12
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 10
- 230000009189 diving Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 235000010288 sodium nitrite Nutrition 0.000 description 9
- 238000012549 training Methods 0.000 description 9
- 239000003390 Chinese drug Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229960004526 piracetam Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- 208000036626 Mental retardation Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- CMVHOLZLFLESKY-UHFFFAOYSA-N Anisodine Natural products CN1C2CC(CC1C3OC23)C(=O)OC(O)(CO)c4ccccc4 CMVHOLZLFLESKY-UHFFFAOYSA-N 0.000 description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 5
- 206010027374 Mental impairment Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- JEJREKXHLFEVHN-QDXGGTILSA-N anisodine Chemical compound C1([C@](O)(CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 JEJREKXHLFEVHN-QDXGGTILSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 3
- 208000002381 Brain Hypoxia Diseases 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000007905 drug manufacturing Methods 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- YFSUTJLHUFNCNZ-UHFFFAOYSA-M 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-M 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010057315 Daydreaming Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 208000001705 Mouth breathing Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001777 nootropic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical class OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- IYPRWQPJYRBHIS-UHFFFAOYSA-N acetic acid;uranium Chemical compound [U].CC(O)=O IYPRWQPJYRBHIS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000000444 liquid chromatography-electrochemical detection Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- RPUFERHPLAVBJN-UHFFFAOYSA-N n,n-dihydroxy-1-phenylmethanamine Chemical compound ON(O)CC1=CC=CC=C1 RPUFERHPLAVBJN-UHFFFAOYSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an intelligence developing and brain nourishing medicine, particularly to a traditional Chinese intelligence developing and brain nourishing medicine. The medicine of the present invention mainly comprises 325 to 425g of fleece-flower roots, 150 to 200g of arborvitae seeds, 100 to 150g of longan aril, 325 to 425g of rhizoma polygonati, 325 to 425g of glossy privet fruits, 325 to 425g of mulberry fruits, 150 to 200g of lotus seeds and 150 to 200g of senega. The present invention is verified by pharmacodynamics, toxicology and stability experiments and clinical treatment to have the obvious efficacies of heart and kidney invigoration, blood nourishment, liver conditioning, brain tonifying and intelligence intensification. The total effective rate of MR treatment of the present invention is clinically observed to be 82%, and the total effective rate of MBD treatment is 96%.
Description
The present invention relates to promoting intelligence and strengthening brain Chinese medicine.
Domestic focusing on the Chinese herbal medicine of relevant nootropic action research in recent years, with the research of Fructus Alpiniae Oxyphyllae tonics at most, Xu Shi treats slight disordered brain function 20 examples with cephalocathartic Fructus Alpiniae Oxyphyllae mixture especially.Cephalocathartic Fructus Alpiniae Oxyphyllae composition medicine is formed: harts horn carbon 6g, Radix Rehmanniae Preparata 20g, Fructus Amomi 4.5g, Os Draconis 30g, Carapax Et Plastrum Testudinis (processed) 15g, Rhizoma Acori Graminei 9g, Cortex et Radix Polygalae (processed) 3g, Radix Salviae Miltiorrhizae 15g, Fructus Alpiniae Oxyphyllae 6g, Fructus Lycii 9g, water decoction.1 dose of every day, 2 times for oral administration, serve on 2 months.Function: training replenishing vital essence and blood, regulating YIN and YANG, the Fructus Alpiniae Oxyphyllae of having one's ideas straightened out.Therapeutic outcome, produce effects 11 people (55%), progressive 6 people (30%), invalid 3 people (15%) (seeing child's minimal brain dysfunction (MBD) syndromic Chinese traditional treatment-20 example reports such as Xu Jun crown, combination of Chinese and Western medicine magazine 1,982 2 (1) 22-24).
Zhang Shi treats mental retardation of children 40 examples with the refreshment health, and refreshment health medicine is formed: Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Angelicae Sinensis etc. are processed into refreshment health concentrated solution, according to age increase and decrease dose, every day 3 times, three months courses of treatment.No matched group, square medicine function: invigorate blood circulation for the stasis of blood (seeing refreshment health treatment mental retardation of children 40 examples such as Zhang Huifen, combination of Chinese and Western medicine magazine 1988 (10) 640).
Zou Shi adopts " Fructus Alpiniae Oxyphyllae spirit " to promote child intelligence to grow, clinical observation 50 examples, and wherein 17 examples are organized in treatment, matched group 34 examples.Fructus Alpiniae Oxyphyllae miraculous cure thing is formed: Radix Ginseng Rubra 1.5g, Radix Ginseng 1.5g, Arillus Longan 10g, Fructus Schisandrae Chinensis 3g, Rhizoma Dioscoreae 15g, Poria 10g etc.Make dissolved granule with medicine-feeding, 15-20g/ time, 2-3 time/day, 3 months is 1 course of treatment.Side's medicine function: the reinforcing the heart spleen, open surreptitiously Fructus Alpiniae Oxyphyllae.Therapeutic outcome, the group of taking medicine IQ meansigma methods be significantly improved (see: Zou's stannum is listened etc., and the Fructus Alpiniae Oxyphyllae spirit promotes the clinical observation that child intelligence is grown, journal of shanghai Chinese medicine 1988 (1) 10-12).
In a word, more than three kinds of medicines to increasing intelligence certain curative effect is arranged, but effective percentage is still not high.
The present invention is exactly at the problems referred to above, provides a kind of cure rate high medicine with intelligence increasing and brain tonic function.
The object of the present invention is achieved like this, and this medicine mainly adopts following medicine to form:
Radix Polygoni Multiflori 325-425g Semen Platycladi 150-200g Arillus Longan 100-150g
Rhizoma Polygonati 325-425g Fructus Ligustri Lucidi 325-425g Fructus Mori 325-425g
Semen Nelumbinis 150-200g Radix Polygalae 150-200g
Radix Polygoni Multiflori, Semen Platycladi, Arillus Longan, Rhizoma Polygonati four medicines are main in the side.Radix Polygoni Multiflori invigorating the liver and kidney essence and blood; The Semen Platycladi tranquilizing by nourishing the heart, loosening bowel to relieve constipation; The Arillus Longan heart-spleen boosting fills blood and calms the nerves; The Rhizoma Polygonati reinforcing spleen and kidney, profit heart spleen, strong soul is obeyed in bone and muscle strengthening for a long time, and is clever.
Fructus Ligustri Lucidi, Fructus Mori, Semen Nelumbinis, Radix Polygalae four flavors are to assist to hold up the principal agent invigorating heart and kidney, the profit that nourishes blood liver.The Fructus Ligustri Lucidi invigorating the liver and kidney, strong waist knee joint, settling five organs is supported spirit; Fructus Mori the liver and the kidney tonifying, peace soul, sharp the five internal organs; Semen Nelumbinis the heart nourishing and intellengence improving, Radix Polygalae calm the nerves Fructus Alpiniae Oxyphyllae, peace soul, strong will times power.
Major advantage of the present invention:
The active drug of the improvement intelligence that this medicine system is made by pure Chinese medicine.Through pharmacodynamics, toxicology and stability experiment and clinical verification, have tangible invigorating heart and kidney, the profit that nourishes blood liver, brain-strengthening is wise, fill out the strong body of marrow, the effect of nourishing the brain and improving intelligence, can promote intellectual development, improve IQ, hypermnesis, improve thinking, can regulate and promote brain function to recover, through clinical observation treatment MR total effective rate 82%, treatment MBD total effective rate 96%.
This medicine can promptly can be made into pill by actual needs, also can be made into the form of powder or oral liquid, and this also all is conventional technique processing method certainly.
Embodiment:
(1) the clinical and experimentation (mental retardation abbreviates MR as) of treatment MR
1. clinical data MR70 name all is that intelligence, training school's case are educated in Hospital Attached to Liaoning Inst. of Traditional Chinese Medicine Pediatric Clinic and urban district, Shenyang in the period of the 1988-1990, male 40 examples, and women 30 examples divide observation group 50 example and matched group 20 examples at random.10 years old observation group's mean age, 11 years old matched group mean age.
2. diagnostic criteria:
1) tcm diagnosis standard: down in spirits, have a dull expression on one's face, lusterless complexion, hypoevolutism, mental incapacity.Slurred speech, active, absent minded, poor memory, school grade obviously falls behind, red tongue or red, few tongue or no fur, deep-thready pulse.
2) with reference to WHO1985 mental retardation standard revision standard:
(1) integration capability (language, memory, study, life, social adaptation) is lower than the child of the same age.
(2) morbidities in the past in 14 years old
(3) IQ index (IQ) is lower than 75.Mental retardation person due to the brain organic diseases such as autosomal abnormalities, innate immunity defective, various brain disorder sequela except needing.IQ is measured and is adopted Haskell Wexler-Liaoning 1986 revision scales.Respectively detect 1 time before and after the treatment, and judge with reference to other index comprehensives.
3. medicine and technology
Radix Polygoni Multiflori (system) 375g Semen Platycladi 175g Arillus Longan 125g
Rhizoma Polygonati 375g Fructus Ligustri Lucidi 375g Fructus Mori 375g
Semen Nelumbinis 175g Radix Polygalae 175g Poria 75g
Os Draconis 300g Bulbus Lilii 175g Radix Salviae Miltiorrhizae 250g
Ethyl hydroxybenzoate 0.1g white sugar 100g propylparaben 0.1g
Make 1000ml altogether.
[method for making] above 12 flavors add decocting, fry in shallow oil three times, add 7 times of amounts of water for the first time, flood 2 hours, decoct 1.5 hours, filter.For the second time add 5 times of amounts of water, decocted 1 hour, filter.Add 3 times of amounts of water for the third time, decocted 0.5 hour, filter.Merging filtrate leaves standstill more than 24 hours filtration under diminished pressure.Filtrate decompression is concentrated into no more than 925ml, adds white sugar ethyl hydroxybenzoate and propyl ester and stirs and to make dissolving, adds distilled water again to 1000ml, detects liquid PH value (being 4.5-5.5), after relative density (being 1.10-1.16) is qualified, and filtration under diminished pressure again.Fill, sterilization, promptly.
4. observational technique
The oral liquid of the oral medicine with intelligence increasing and brain tonic function of observation group is obeyed every day 2 times sooner or later, each every year old 1ml below 10 years old, and each 10ml more than 10 years old, 4 months is a course of treatment.Matched group adopts the intelligence training method.
5. efficacy determination
Produce effects: integration capability obviously improves, and IQ improves more than 15, and the traditional Chinese medical science is examined and seen that speech is clear, hypermnesia, and intelligence improves.
Take a turn for the better: integration capability increases, or certain intelligence (language, memory, understanding, operation) is obvious, and IQ improves more than 10; The traditional Chinese medical science is examined and is seen that speech is clearer, and memory before has enhancing, and intelligence increases.
Effectively: integration capability has raising, and IQ improves more than 5, and the traditional Chinese medical science is examined and seen that speech or memory have improvement, and intelligence slightly improves.
Invalid: every intelligent index slightly improves or no change.
6. observed result:
Total effective rate: observation group 82%, matched group 15% is learned by statistics and is handled P＜0.005 difference highly significant, sees Table I for details.
Experimentation:
Adopt multiple model and method, inquired into the influence of the oral liquid of medicine with intelligence increasing and brain tonic function to animal learning memory, behavior, simultaneously from molecular level, subcellsular level has carried out comparatively deep research to its maincenter pharmacological mechanism.
Curative effect statistics before and after mental retardation observation group and the treatment of control group
Subordinate list 1
Total IQ (IQ) PIQ (IQ) linguistic IQ (IQ)
Treatment group treatment of control group group treatment of control group group matched group
The routine number % example of example number % number % example number % example number % example number % produce effects 13 26 11 11 17 111 11 11 9 10 11 11 improvements 12 24 11 11 111 211 11 11 12 21 11 11 effective 16 32 8 15 0 16 3 15 18 36 5 25 invalid 9 10 17 0.5 11 26 17 0.5 15 30 15 75 total effective 41 82 3 15 17 74 3 15 15 70 5 25XT, 31.5 22.4 14P＜0.005 0.005 0.005
Materials and methods
(1) laboratory animal:
1. Kunming kind healthy mice, body weight 9-11g, the male and female dual-purpose, Chinese Medical Sciences University's Experimental Animal Center provides.
2.Wistar male white rat, body weight 150-200g, animal housing of Traditional Chinese Medicinal College of Liaoning provides.
(2) medicine and method
Medicine with intelligence increasing and brain tonic function is provided by the Hospital Attached to Liaoning Inst. of Traditional Chinese Medicine Drug Manufacturing Room.
1. learning and memory behavioral experiment
(1) medicine: piracetam is hated by herbal pharmacology teaching and research room of Shenyang Pharmacy College favour; Anisodine is hated by the institute of Materia Medica,Chinese Academy of Medical Sciences favour, and sodium nitrite and ethanol are the commercial reagent.
(2) experiment grouping: get 150 of mices, be divided into the blank group at random; Pathological model group (causing learning and memory to obtain, consolidate and reproduce the pathological model of obstacle for respectively Anisodine, sodium nitrite, 40% ethanol); The oral liquid I group of medicine with intelligence increasing and brain tonic function; The oral liquid II group of medicine with intelligence increasing and brain tonic function, the piracetam group.
(3) instrument: by imitated the forming of disposable training, avoidance conditioned reflex case of Zhang Juntian report.[1]
The diving tower reflective box is 20 * 20 * 30cm
3Wooden (-packing) case is the copper grid at the bottom of the case, passes to 40V electric current, case built-in one high 3.5cm, the valve rubber of diameter 5cm.The place of safety of avoiding electric shock as animal.
Keeping away dark reflective box is 40 * 15 * 15cm
3Glass box, divide light and shade two Room, the bottom, darkroom be the copper grid, passes to the 40V electric current, has the little edge of a diameter 3cm to communicate between two Room, bright chamber is that animal is avoided the place of safety of shocking by electricity.
(4) method: press document
[1]The report method.Blank group and pathological model group all gavage to normal saline before the experiment, meanwhile oral liquid I, the II of medicine with intelligence increasing and brain tonic function group and piracetam group gavage for respectively the oral liquid and the piracetam of the medicine with intelligence increasing and brain tonic function of various dose, secondary every day (early, evening respectively once).Continuous 10d.Train behind the last oral liquid of giving normal saline, medicine with intelligence increasing and brain tonic function and the piracetam, once training back 24h formally tests.Observation to learning and memory obtain influence the time, with each group mice 15min lumbar injection Anisodine 5mg/kg before training; Observation is consolidated when influence memory, subcutaneous injection sodium nitrite 120mg/kg immediately after training; When observation influenced memory represents, 10min gavaged 40% ethanol 0.1ml/10g body weight before the 24h test of training back.
(1) step down test: after during training mice being placed on reflective box endoadaptation 3min, energising 5min, record jumps off electric shock number of times (being errors number) from platform; Formally test behind 24h then, errors number in the record 3min is respectively as the observation index that memory is obtained, consolidates and reproduce.
(2) keep away dark test; Animal pierces in incubation period (pierce for the first time darkroom before time) in darkroom and the 5min and pierces the number of times in darkroom as observation index in the record test.
Above-mentioned two kinds of tests all can be observed the influence of the acquisition of oral liquid learning and memory, consolidation and the reproduction of medicine with intelligence increasing and brain tonic function by giving the learning and memory blocker of different links, all belong to the test of passive avoidance trained reflex.
Significance with bilateral " t " method of inspection analysis bank differences
2. brain acute anoxia experiment
(1) medicine: piracetam is so kind as to give by herbal pharmacology teaching and research room of Shenyang Pharmacy College; Sodium nitrite is Shenyang reagent one factory's product.
(2) grouping and administration: get 120 of mices, be divided into four groups at random, the normal saline group gavages to normal saline before the experiment, meanwhile oral liquid I, the II of medicine with intelligence increasing and brain tonic function group and piracetam group gavage oral liquid 12g crude drug/kg, the 36g crude drug/kg of medicine with intelligence increasing and brain tonic function respectively, piracetam 300mg/kg, secondary every day (early, evening each once) continuous 8 days, experimentizes behind the last administration 1b.
(3) method:
(1) broken end ischemia method:
[2]Cut mouse head, the mouth breathing with stopwatch record decapitated mice immediately continues time-histories.
(2) anoxia that causes of the sodium nitrite method that causes death:
[3]Give mouse subcutaneous injection sodium nitrite 225mg/kg once, record injection back is to the time of respiratory arrest.
(3) normobaric hypoxia method:
[4]Mice is put into the 250ml wide mouthed bottle that fills the 10g sodica calx, and bottleneck is coated with vaseline airtight, and the time-to-live of mice under the normobaric hypoxia state respectively organized in record.
Significance with bilateral " t " check analysis group difference.
3. focal cerebral ischemia rat brain born of the same parents Ultrastructural observation
Get 12 of rats, be divided into three groups at random, before the experiment, Chinese drug-treated group adopts free drinking technique to give the oral liquid 20g/kg of medicine with intelligence increasing and brain tonic function; Matched group and model group are given tap water, continuous 15 days with method.All use nembutal 40mg%kg intraperitoneal anesthesia during experiment.
(1) ligation right carotid
Behind the rat anesthesia, press document
[5,8]Method is isolated right carotid.Do not do ligation behind 4 rat surgical exposure of matched group common carotid artery; After model group and the Chinese drug-treated group surgical exposure right carotid, all do dual ligation, cut off for 4 every group at the ligation mid point.Broken end is got brain after 24 hours, gets cerebral cortex top fixation of tissue in 2.5% glutaraldehyde.
(2) pathologic finding:
Mus brain specimen starves through 1% that acid is fixing, ethanol acetone dewaters step by step, epoxy resin 618 embeddings again after 2.5% glutaraldehyde is fixing, ultrathin section, citron lead plumbate and the dyeing of acetic acid uranium, the saturating body electron microscopic observation of H-600.
4. monoamine neurotransmitters is measured in the mouse brain
(1) grouping: get 40 of mices, divide four groups at random, 10 every group, i.e. blank group, pathologic group, treatment group, Chinese drug-treated group.
(2) give approximately: the reserpine injection is
The state
Light restriction factory product.Blank group subcutaneous injection every day normal saline 0.1ml/10g gavages normal saline 0.2ml/10g simultaneously; Pathologic group subcutaneous injection of reserpine every day one physiology saline 0.25mg/kg, gavage normal saline 0.2ml/kg simultaneously, gavage the oral liquid 12%0.2ml/10g of medicine with intelligence increasing and brain tonic function simultaneously, Chinese drug-treated group subcutaneous injection every day normal saline 0.1ml/10g gavages the oral liquid 120%0.2ml/10g of medicine with intelligence increasing and brain tonic function simultaneously.Below respectively organize equal successive administration 8 days.
(3) method
High performance liquid chromatography-electrochemistry inspection hand hay cutter device (EPLC-ECD) monoamine neurotransmitter algoscopy.
(1) reagent
Methanol (AR), citric acid (A, R), di-n-butylamine (CR),
Sodium acetate (AR), EB
2EDTA
Shenyang reagent one factory's product
Perfluorooctane sulfonate, Sigeb company product
Norepinephrine (RE), dopamine (DA),
5-hydroxy tryptamine (5-HT), 5-hydroxyindoleacetic acid (5-DIAA)
3,4 dihydroxyphenyl acetic acids (DDPAC), dihydroxy benzylamine (DHBA)
Be Sigxa company and Kerck company product
Perchloric acid (AR) Shenyang reagent one factory's product
(2) instrument
The katers510 constant flow pump; 460 electrochemical detectors; Glass-carbon electrode; Resolve 5 μ Spherical cl6 chromatographic columns, 150 * 3.9mml/O; The U6k injector, 740 integrators.
(3) chromatographic condition
Flow rate pump 1.0ml/min, running voltage+0.70v, oxidizing process.Detection sensitivity 10nA; Chart speed 30cm/b; 20 ± 2 ℃ of room temperatures.
Mobile phase is formed: 50mmol/L sodium acetate, 20mmol/L citric acid, 1mmol/L perfluorooctane sulfonate, 1mmol/L di-n-butylamine, 0.2mmol/L, Rb
2EDTA, 2-4% methanol.With the preparation of deionization redistilled water, it is 4 that citric acid is transferred PH, and mixing filters ultrasonic degasification.
(4) standard substance and sample preparation
Standard substance preparation: standard substance NE, DA, 5-HT, 5-HIAA, DDFAC and interior mark DHBA are dissolved in 0.1mol/L, ECLD
4In the solution, be mixed with 10ng/ml concentration, put cryopreservation in the refrigerator, face with preceding and be diluted to a series of debita spissitudos with corresponding solvent.
Sample preparation: will get brain rapidly behind the mice broken end, decerebellation weigh and promptly put-40 ℃ of refrigerators freezing after, add 2mg/L DHBA50ml, cold 0.1mol/L perchloric acid 2ml makes homogenate (being cold operation), pour into then in the centrifuge tube in 4 ℃ 18000 rev/mins, centrifugal 30min gets supernatant 20 μ l direct injected.
(5) result calculates
The ratio of every kind of material peak height and DHBA peak height is made comparisons with the ratio in the standard substance in the sample, calculates the content of every gram wet tissue monoamine transmitters in the sample.Referring to Fig. 1,2.
Significance with bilateral " t " check analysis group difference
Result and analysis
(1) learning and memory behavioral experiment
1. the oral liquid of medicine with intelligence increasing and brain tonic function obtains bad to influence model group (giving Anisodine) and blank group relatively to learning and memory due to the Anisodine, and diving tower method experiment errors number obviously increases, and (P＜0.01) is obviously shortened in the darkness avoidance test test incubation period; Oral liquid I, the II group and the model group of medicine with intelligence increasing and brain tonic function compare, diving tower method errors number obviously reduces (P＜0.05, P＜0.01), and II organizes darkness avoidance test significant prolongation incubation period (P＜0.05), compare with model group, diving tower method experiment errors number significantly reduces (P＜0.05).See Table 1.
2. the oral liquid of medicine with intelligence increasing and brain tonic function is consolidated bad influence to memory due to the sodium nitrite
Pathological model group (give sodium nitrite) and blank group relatively, diving tower experiment errors number significantly increases, and keeps away dark experiment and obviously shortens (P＜0.01) incubation period; Oral liquid I, the II of medicine with intelligence increasing and brain tonic function group and pathological model group relatively, diving tower with keep away dark experiment errors number and all significantly reduce (P＜0.01, P＜0.05) test and obviously calculate long (P＜0.01) incubation period.Piracetam and model group relatively, diving tower with keep away dark experiment errors number and also significantly reduce (P＜0.05), long (P＜0.05) is obviously calculated in test incubation period.See Table 2.
3. the oral liquid of medicine with intelligence increasing and brain tonic function is to the bad influence of memory represents due to 40% ethanol
Pathological model group (give 40% ethanol) and blank group relatively, diving tower experiment errors number obviously increases, darkness avoidance test obviously shortens (P＜0.01) incubation period; Oral liquid I, the II group and the pathology matched group of medicine with intelligence increasing and brain tonic function compare, and diving tower experiment errors number significantly reduces (P＜0.01), darkness avoidance test significant prolongation incubation period (P＜0.05).Piracetam group and model group compare, and diving tower experiment errors number obviously reduces (P＜0.05).See Table 3.
(2) oral liquid of medicine with intelligence increasing and brain tonic function is to the influence of period of development chmice acute cerebral anoxia state
In the broken end ischemia method, oral liquid I, the II group average mouth breathing time of mice of medicine with intelligence increasing and brain tonic function is all significantly calculated long (P＜0.01) than the matched group time, sodium nitrite anoxia method, the oral liquid II group death time of piracetam and medicine with intelligence increasing and brain tonic function is all significantly calculated long (P＜0.05, P＜0.01) than matched group.In the experiment of normal pressure anoxia enduring, the oral liquid II group of piracetam group and medicine with intelligence increasing and brain tonic function all can prolong its life span (P＜0.05, P＜0.01).See Table 4.
(3) oral liquid of medicine with intelligence increasing and brain tonic function is to the Ultrastructural effect of focal rats with cerebral ischemia brain cell
1. matched group: mitochondrion quantity is more, and rounded or elongated shape, ridge are tabular or tubulose, and basic southern endoparticle is less.Endoplasmic reticulum often is close under the plasma membrane gathers multilamellar.Golgi complex is flourishing.(see figure 3).
2. model group: mitochondrial swelling, ridge disappear and are cavitation, and cellularity such as endoplasmic reticulum and Golgi complex are in various degree and change, and the cytoplasmic matrix electron density increases (seeing Fig. 4,5).
3. Chinese drug-treated group: the mitochondrion mild swelling, ridge exists, ridge quantity is bordering on normally, the cytoplasmic matrix electron density still can, other organelles do not have obvious change (seeing Fig. 6,7).
(4) oral liquid of medicine with intelligence increasing and brain tonic function is to the influence of monoamine neurotransmitter in the period of development mouse brain
1.RE concentration
Pathologic group (giving reserpine) compares with the blank group, and RE concentration significantly reduces (P＜0.01): treatment group and pathologic group compare, and RE concentration obviously increases (P＜0.01); Chinese drug-treated group and blank group compare, and RE concentration also increases (P＜0.05).
2.DA, DDPAC concentration
Pathologic group (giving reserpine) compares with the blank group, and DA concentration significantly reduces.DDPAC concentration is 0 (P＜0.01); Treatment group and pathologic group compare, and DA concentration obviously increases (P＜0.01); Chinese drug-treated group and blank group compare, and DA concentration also increases (P＜0.05).
3. 5-HT and 5-HIAA concentration pathologic group (giving reserpine) compare with the blank group, and 5-HT concentration significantly reduces (P＜0.01), though 5-HIAA concentration descends, does not have significant difference; Treatment group and pathologic group compare, and 5-HT concentration obviously reduces (P＜0.01), though 5-HIAA concentration reduces, difference does not have significance; Chinese drug-treated group and blank compare, no significant difference.
Conclusion:
(1) oral liquid of medicine with intelligence increasing and brain tonic function has facilitation to learning and memory function.
(2) the anti-acute brain anoxia functions of the oral liquid of medicine with intelligence increasing and brain tonic function and its memory improvement effect are closely related.
(3) oral liquid of medicine with intelligence increasing and brain tonic function may be that it promotes mechanism intelligent, that delay intellectual damage to the protective effect of cerebral cortex cell.
(4) oral liquid of medicine with intelligence increasing and brain tonic function promotes that the effect of learning and memory is relevant with monoamine neurotransmitter in the brain, and NE, DA concentration increase, and the 5-HT lowering of concentration may be the pharmacological Mechanism of its nootropic effect.
(2) treatment MBD80 example report (slight disordered brain function syndrome is called for short MBD)
1. clinical data
The MBD80 example all is institute of a section Pediatric Clinic case in the period of the 1988-1991,52 of men, and 26 of woman, divide observation group 50,30 of matched groups at random at 9.3 years old mean age.
2. diagnostic criteria
(1) the IQ index descends level (being lower than standard deviation of average) between two parties.
(2) understand, memory ability falls behind, hyperactivity, absent minded, learning difficulty (due to the various diseases except the person) is arranged in various degree.
3. medicine
The oral liquid of medicine with intelligence increasing and brain tonic function: Radix Polygoni Multiflori 325g, Semen Platycladi 150g, Arillus Longan 100g, Rhizoma Polygonati 325g, Fructus Ligustri Lucidi 325g, Fructus Mori 325g, Semen Nelumbinis 150g, Radix Polygalae 150g, Os Draconis 250g, Bulbus Lilii 150g, Radix Salviae Miltiorrhizae 225g, Poria 50g.
Technology: decocting-concentration method (providing) by the Drug Manufacturing Room of Traditional Chinese Medicinal College of Liaoning.
4. observational technique:
The oral liquid of the oral medicine with intelligence increasing and brain tonic function of observation group is obeyed every day 2 times sooner or later, each every year old 1ml below 10 years old, and each 10ml more than 10 years old, 4 months is a course of treatment.The oral piracetam of matched group, each 0.1, every day 3 times.
5. efficacy determination
Produce effects: school grade obviously improves, and hyperactivity obviously reduces, and the memory attention strengthens; The IQ index obviously improves.
Take a turn for the better: school grade, memory have certain amplitude to improve, and hyperactivity reduces, and the IQ index has raising.
Invalid: no change before and after the treatment.
6. therapeutic outcome:
Observation group's total effective rate 96%, matched group total effective rate 53% is learned by statistics and is handled P＜0.05, difference highly significant.See Table II for details.
Table II MBD observation group and matched group coefficient ratio are
The matched group P of project observation group
Example (%) example (%)
Produce effects 24 (50) 5 (16)＜0.005
Take a turn for the better 23 (46) 11 (39)
Invalid 2 (4) 14 (47)
Total effective 48 (96) 16 (53)
(3) treatment MR10 example report
1. clinical data
The MR10 example is Shenyang Inst. of Traditional Chinese Medicine's Pediatric Clinic case, male 8 examples, women 2 examples, 6.5 years old mean age.
2. diagnostic criteria.Same embodiment (one), the same embodiment of curative effect determinate standard ().
3. medicine and technology:
Radix Polygoni Multiflori 375g Semen Platycladi 175g Arillus Longan 100g Rhizoma Polygonati 350g
Fructus Ligustri Lucidi 375g Fructus Mori 325g Semen Nelumbinis 175g Radix Polygalae 175g
Technology: decocting-concentration method.
3. observational technique: the oral liquid of medicine with intelligence increasing and brain tonic function, each every year old 1ml, sooner or later oral every day 2 times, total 4 months courses of treatment.
Therapeutic outcome: produce effects 3 people, 3 people that take a turn for the better, effective 3 people, invalid 1 people.Total effective rate 90%.
(4) treatment neurasthenia, alzheimer disease, 30 example reports:
1. clinical data
My institute's internal medicine outpatient service is equipped with example, wherein male 18 examples, women 12 examples, 52 years old mean age in the period of all being equipped with examples and all being 1989-1992.
2. diagnosis and curative effect determinate standard are with reference to practical internal medicine standard.
3. medicine and technology
Radix Polygoni Multiflori 425g Semen Platycladi 200g Arillus Longan 150g Rhizoma Polygonati 425g
Fructus Ligustri Lucidi 425g Fructus Mori 425g Semen Nelumbinis 200g Radix Polygalae 200g
Poria 100g Os Draconis 350g Bulbus Lilii 200g Radix Salviae Miltiorrhizae 275g
Technology: decocting-concentration method is provided by the Drug Manufacturing Room of Traditional Chinese Medicinal College of Liaoning.
Observational technique: the oral liquid of medicine with intelligence increasing and brain tonic function, each 20ml obeys every day 2 times sooner or later, and 1-3 month is a course of treatment.
Therapeutic outcome: produce effects 12 examples (40%), 10 examples that take a turn for the better (33.3%), effective 6 examples (20%), invalid 2 examples (6.7%), total effective rate 93.3%.
The promoting intelligence and strengthening brain drug effect studies confirm that anti-acute brain anoxia functions, and the cerebral cortex cell is had protective effect, can delay the intelligence wound; so Yu Yonger adult neurasthenia, alzheimer disease, therapeutic outcome, total effective rate reaches 93.3%; illustrate that this oral liquid has slow down aging, the protection function of brain cell.
(5) anxious, slow toxicity test of the oral liquid of medicine with intelligence increasing and brain tonic function and medicine stability experiment:
1. anxious malicious conclusion (of pressure testing): irritate oral liquid 175g crude drug/kg that stomach gives the mice medicine with intelligence increasing and brain tonic function, be equivalent to 175 times of clinical child's consumption, mice does not have tangible poisoning manifestations, discloses the clinical a drug safety of this medicine.
2. long term toxicity test conclusion: continuous 12 weeks gavage oral liquid 19.6-79.2 (crude drug) 1kg of medicine with intelligence increasing and brain tonic function to rat oral, the 10-40 that is equivalent to child's one consumption per day more than 10 years old doubly, except that the high dose rat body weight increasess slowly, blood system, hepatic and renal function and pathologic finding etc. are not all had significantly influence, and this agent is taken in prompting does not for a long time have tangible accumulate poisoning reaction.
3. medicine stability test conclusion: the oral liquid of medicine with intelligence increasing and brain tonic function is through reserved sample observing 18 months, its character, and pH value, relative density, check result all meets the requirements.The discriminating item is checked out Radix Polygoni Multiflori, Fructus Mori.Health examination, assorted bacterium number, fungi count, yeast number average meet " ministry standard " version in 1986.Without going out escherichia coli, demodicid mite alive.Therefore, assert that this product is stable, qualified.
Claims (4)
1, a kind of medicine with intelligence increasing and brain tonic function is characterized in that it being to be made by raw material Radix Polygoni Multiflori 325-425g, Semen Platycladi 150-200g, Arillus Longan 100-150g, Rhizoma Polygonati 325-425g, Fructus Ligustri Lucidi 325-425g, Fructus Mori 325-425g, Semen Nelumbinis 150-200g, Radix Polygalae 150-200g substantially.
2, medicine with intelligence increasing and brain tonic function according to claim 1 is characterized in that making 1000ml altogether by Radix Polygoni Multiflori 375g, Semen Platycladi 175g, Arillus Longan 125g, Rhizoma Polygonati 375g, Fructus Ligustri Lucidi 375g, Fructus Mori 375g, Semen Nelumbinis 175g, Radix Polygalae 175g, Poria 75g, Os Draconis 300g, Bulbus Lilii 175g, Radix Salviae Miltiorrhizae 250g, ethyl hydroxybenzoate 0.1g, white sugar 100g, propylparaben 0.1g.
3, the intelligence key brain medicine that increases according to claim 1 is characterized in that Radix Polygoni Multiflori 325g, Semen Platycladi 150g, Arillus Longan 100g, Rhizoma Polygonati 325g, Fructus Ligustri Lucidi 325g, Fructus Mori 325g, Semen Nelumbinis 150g, Radix Polygalae 150g, Os Draconis 250g, Bulbus Lilii 150g, Radix Salviae Miltiorrhizae 225g, Poria 50g.
4, medicine with intelligence increasing and brain tonic function according to claim 1 is characterized in that Radix Polygoni Multiflori 425g, Semen Platycladi 200g, Arillus Longan 150g, Rhizoma Polygonati 425g, Fructus Ligustri Lucidi 425g, Fructus Mori 425g, Semen Nelumbinis 200g, Radix Polygalae 200g, Poria 100g, Os Draconis 350g, Bulbus Lilii 200g, Radix Salviae Miltiorrhizae 275g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93110081A CN1048877C (en) | 1993-02-12 | 1993-02-12 | Medicine with intelligence increasing and brain tonic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93110081A CN1048877C (en) | 1993-02-12 | 1993-02-12 | Medicine with intelligence increasing and brain tonic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1091023A CN1091023A (en) | 1994-08-24 |
| CN1048877C true CN1048877C (en) | 2000-02-02 |
Family
ID=4987989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93110081A Expired - Fee Related CN1048877C (en) | 1993-02-12 | 1993-02-12 | Medicine with intelligence increasing and brain tonic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1048877C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103238699A (en) * | 2013-06-07 | 2013-08-14 | 北京绿源求证科技发展有限责任公司 | Food health tea soluble granules for nourishing brain |
| CN103637203A (en) * | 2013-12-08 | 2014-03-19 | 哈尔滨升益生物科技开发有限公司 | Formula and preparation method of brain tonifying and strengthening lotus seed soup base |
| CN106362065A (en) * | 2016-10-21 | 2017-02-01 | 代立新 | Traditional Chinese medicine with effects of improving intelligence and strengthening brains and method for preparing traditional Chinese medicine |
| CN108310205A (en) * | 2018-01-16 | 2018-07-24 | 佛山科学技术学院 | It is a kind of that there is the brain tonic cream and preparation method thereof for removing free radical function |
| CN109512939A (en) * | 2018-12-26 | 2019-03-26 | 刘焯 | Treat mental retardation, difficulty of learning and mostly dynamic Chinese medicine composition and Chinese materia medica preparation |
| CN110123947A (en) * | 2019-06-05 | 2019-08-16 | 大连博格林生物科技有限公司 | Improve the Chinese materia medica preparation of memory |
-
1993
- 1993-02-12 CN CN93110081A patent/CN1048877C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1091023A (en) | 1994-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1233387C (en) | Chinese compound medicine for treating anhypnosis and its preparation metod | |
| CN1119164C (en) | Medicine for treating chronic incomplete renal function and its prepn | |
| CN1048877C (en) | Medicine with intelligence increasing and brain tonic function | |
| CN1238024C (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1136931A (en) | Ant ginseng oral liquid and preparing process thereof | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1813868A (en) | Composition for treating and improving chronic fatigue syndrome and its preparing method | |
| CN1290529C (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1526440A (en) | Compound Chinese medicine prepn for treating muscular atrophy and amyasthenia and its prepn process | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1197611C (en) | Medicine for curing choleithiasis and preparing method thereof | |
| CN1824185A (en) | A traditional Chinese medicine composition for treating insomnia, functional dyspepsia and constipation and preparation method thereof | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1235841C (en) | Method for preparing extract of peanut leaf | |
| CN1650895A (en) | Method of extracting medicamout having memory strengthening function from natural plant compound preparation | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1562114A (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN1831015A (en) | Process for extracting fructus ligustri lucidi and Radixa stragali polysaccharide, the products and application thereof | |
| CN1810271A (en) | Chinese medicine composition for treating apoplexy and its prepn process and use | |
| CN1314415C (en) | Skin disease treating Chinese traditional medicine | |
| CN1290566C (en) | Depression treating medicinal formulation and its preparation process | |
| CN1679693A (en) | Medicine for treating hepatopathy and preparation thereof | |
| CN1282470C (en) | Traditional Chinese medicine for anti depression | |
| CN1442164A (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1562272A (en) | Medication for curing secondary anemia, iron deficiency anemia and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUIREN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HOSPITAL ATTACHED TO LIAONING INST. OF TRADITIONAL CHINESE MEDICINE Effective date: 20011112 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20011112 Address after: 330043 No. 1189 Yingbin Road, Jiangxi, Nanchang Patentee after: Huiren Pharmaceutical Co., Ltd. Address before: Beiling Street in Huanggu District of Shenyang City, Liaoning Province, No. 33 110032 Patentee before: Affiliated Hospital Liaoning Traditional Chinese Medicine College |
|
| ASS | Succession or assignment of patent right |
Owner name: JIANGXI HUIREN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUIREN PHARMACEUTICAL CO., LTD. Effective date: 20021025 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20021025 Address after: 330002 No. 31 torch street, hi tech Development Zone, Jiangxi, Nanchang Patentee after: Huiren Pharmaceutical Co., Ltd. Jiangxi Address before: 330043 No. 1189 Yingbin Road, Jiangxi, Nanchang Patentee before: Huiren Pharmaceutical Co., Ltd. |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |